

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



Product Data Sheet

PIM-447 dihydrochloride

 Cat. No.:
 HY-19322B

 CAS No.:
 1820565-69-2

 Molecular Formula:
 C24H25Cl2F3N4O

Molecular Weight: 513.38

Target: Pim; Apoptosis

Pathway: JAK/STAT Signaling; Apoptosis

Storage: 4°C, sealed storage, away from moisture

* In solvent: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

HCI

SOLVENT & SOLUBILITY

In Vitro

 $\rm H_2O$: 50 mg/mL (97.39 mM; Need ultrasonic)

DMSO: \geq 46.7 mg/mL (90.97 mM)

* "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|-----------|------------|
| | 1 mM | 1.9479 mL | 9.7394 mL | 19.4787 mL |
| | 5 mM | 0.3896 mL | 1.9479 mL | 3.8957 mL |
| | 10 mM | 0.1948 mL | 0.9739 mL | 1.9479 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PIM447 dihydrochloride (LGH447 dihydrochloride) is a potent, orally available, and selective pan-PIM kinase inhibitor, with K $_{\rm i}$ values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 dihydrochloride displays dual antimyeloma and bone-protective effects. PIM447 dihydrochloride induces apoptosis^{[1][2]}.

| IC ₅₀ & Target | PIM1 | PIM2 | PIM3 |
|---------------------------|------|------|------|
| | | | |

In Vitro

PIM-447?(0.05-10 μ M; 24, 48 and 72 hours) has inhibitory effects in MM cells, it against sensitive cell lines with IC₅₀ values ranging from 0.2 to 3.3 μ M (MM1S, MM1R, RPMI-8226, MM144, U266 and NCI-H929) and less sensitive cell lines with IC₅₀ values at 48 h >7 μ M (OPM-2, RPMI-LR5, U266-Dox4 and U266-LR7)^[1].

Page 1 of 3

PIM-447?(0.1-10 μ M; 24, 48 and 72 hours) does not induce important levels of apoptosis, when PIM447 at 5 μ M, it substantially increases annexin-V levels (about 30%) in sensitive cell lines(MM1S, NCI-H929 and RPMI-8226). When PIM447 at 10 μ M, it induces apoptosis in all the cell lines but to a lesser extent in OPM-2 and RPMI-LR5^[1].

PIM447 promotes the cleavage of initiator caspases, such as caspases 8 and 9, and increases the cleavage of the effector caspases 3 and 7, together with PARP cleavage in MM1S,RPMI-8226 and NCI-H929 cells^[1].

 $PIM447~(0.1-1~\mu\text{M})~increases~the~percentage~of~cells~in~the~G0/G1~phase~and~decreases~the~proliferative~phases~(S~and~G2/M)~of~the~cell~cycle.~The~effects~at~low~concentrations~(0.1-1~\mu\text{M})~were~more~pronounced~in~MM1S~cells~than~in~OPM-2^{[1]}.$

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability $Assay^{[1]}$

| Cell Line: | Sensitive MM cell lines: MM1S, MM1R, RPMI-8226, MM144, U266 and NCI-H929 cells Less sensitive MM cell lines: OPM-2,RPMI-LR5, U266-Dox4 and U266-LR7cells | |
|--------------------------------------|---|--|
| Concentration: | 0.05-10 μΜ | |
| Incubation Time: | 24, 48 and 72 hours | |
| Result: | Was cytotoxic for MM cells (PIM kinases highly expressed). | |
| Apoptosis Analysis ^[1] | | |
| Cell Line: | Sensitive MM cell lines: MM1S, NCI-H929 and RPMI-8226 cells Less sensitive MM cell lines: OPM-2 and RPMI-LR5 cells | |
| Concentration: | 0.05-10 μM | |
| Incubation Time: | 24, 48 and 72 hours | |
| Result: | Induced cell apoptosis at higer doses, had no effects at 0.1-1 uM. | |
| Western Blot Analysis ^[1] | | |
| Cell Line: | Sensitive MM cell lines: MM1S, NCI-H929 and RPMI-8226 cells | |
| Concentration: | 0.05-10 μΜ | |
| Incubation Time: | 24, 48 hours | |
| Result: | Increased the cleavage of the effector caspases 3 and 7, and the PARP cleavage. | |
| Cell Cycle Analysis ^[1] | | |
| Cell Line: | MM1S, OPM-2 cells | |
| Concentration: | 0.1, 0.5 or 1 μM | |
| Incubation Time: | 48 hours | |
| Result: | Increased the cleavage of the effector caspases 3 and 7, and the PARP cleavage. | |

In Vivo

 $PIM447 \ (oral \ gavage; 100\ mg/kg; 5\ times/week)\ clearly\ controlls\ tumor\ progression\ and\ the\ serum\ levels\ of\ hIg\lambda\ secreted\ by\ RPMI-8226-luc\ cells\ in\ mouse\ model\ of\ bone\ marrow-disseminated\ human\ multiple\ myeloma^{[1]}.$

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$

| Animal Model: | RPMI-8226-luc cells are injected intravenously into 6-week-old female NODSCID-IL-2Rγ ^{-/-} |
|---------------|---|
| | (NSG) mice $^{[1]}$ |

Page 2 of 3

| Dosage: | 100 mg/kg |
|-----------------|---|
| Administration: | oral gavage; 100 mg/kg; 5 times/week |
| Result: | Was well tolerated, as the body weight of mice did not decrease by more than 10%. Increased bone volume density and trabecular number and reduced trabecular separation relative to vehicle group. |

CUSTOMER VALIDATION

- Cell Chem Biol. 2023 Nov 16:S2451-9456(23)00384-7.
- J Pathol. 2020 Sep;252(1):65-76.
- Mol Cancer Ther. 2018 Apr;17(4):849-857.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Paíno T et al. The novel pan-PIM kinase inhibitor, PIM447, displays dual anti-myeloma and bone protective effects, and potently synergizes with current standards of care. Clin Cancer Res. 2016 Jul 20.

[2]. Burger MT et al. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies. J Med Chem. 2015 Nov 12;58(21):8373-86.

[3]. Peters TL et al. Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.Oncotarget. 2016 Aug 20

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA